Evotec logo

Evotec

EVO | NASDAQ
Chart Builder DCF Calculator
$1.56
-$0.02 (-1.27%)
At close: Nov 16, 2026, 4:00 PM ET
$1.56
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-1.27%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
40
-1.5 pts
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #531/1021 (Top 52%)

Key Statistics

Market Data

Market Cap $554.08M
1D Range
1.56 1.60
52W Range
1.35 3.87

Valuation (TTM)

PE -3.05
PB 0.76
EV/EBITDA -5.68

Valuation (NTM)

Forward PE 126.20
Forward PEG -0.01
Price Target $3.00
Loading financial charts...

Profile

Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive res...

Sector Healthcare
Employees 4,553
IPO Date Feb 5, 2004
Fiscal Year January - December

Latest News

Evotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth Transcript

8 months ago · seekingalpha.com

Evotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth Transcript
Moving iMage Transforms Eight Screen Santa Fe Theater Complex for EVO Entertainment with Cutting-Edge Laser Projection and Digital Sound Systems, including an EVX Enhanced Viewing Experience Auditorium

9 months ago · newsfilecorp.com

Moving iMage Transforms Eight Screen Santa Fe Theater Complex for EVO Entertainment with Cutting-Edge Laser Projection and Digital Sound Systems, including an EVX Enhanced Viewing Experience Auditorium
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

9 months ago · businesswire.com

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

9 months ago · businesswire.com

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.09
Beat +32.71%
REV
$185.16M
Beat +20.05%
Next Earnings
Apr 14, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
1
Consensus
Buy
Price Target
$3.00
Upside
+92.31%
Buy (1)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.